Verona Pharma (VRNA) Q3 2024 earnings summary

Executive summary

• Ohtuvayre (ensifentrine) launched in the U.S. in August 2024 after FDA approval, marking the first new inhaled COPD therapy in over 20 years, with strong initial demand and positive feedback from patients and healthcare providers.

• Over 5,000 prescriptions were filled in the first 12 weeks, with more than 2,200 unique HCPs prescribing, reflecting broad adoption across all COPD patient types.

• Two new Phase 2 clinical programs were initiated: a fixed-dose combination with glycopyrrolate for COPD and a study in non-CF bronchiectasis.

• Nuance Pharma completed enrollment in a pivotal Phase 3 trial for ensifentrine in China, with results expected in 2025.

• Ohtuvayre launch was supported by positive Phase 3 ENHANCE trials, showing significant improvements in lung function and reduced exacerbations.

Financial highlights

• Ohtuvayre net product sales were $5.6 million for Q3 2024, representing the first partial quarter of sales.

• Net loss after tax was $43.0 million for Q3 2024, compared to $14.7 million in Q3 2023, reflecting increased R&D and SG&A expenses.

• R&D expenses rose to $10.6 million (Q3 2023: $3.0 million); SG&A expenses increased to $35.2 million (Q3 2023: $13.4 million), driven by launch and clinical trial investments.

• Cost of goods sold was $0.5 million for Q3 2024.

• Cash and cash equivalents stood at $336.0 million as of September 30, 2024, up from $271.8 million at year-end 2023.

Outlook and guidance

• October net sales of Ohtuvayre exceeded Q3 totals, indicating accelerating demand.

• Cash, product sales, and up to $650 million in strategic financings are expected to fund operations through at least the end of 2026.

• Additional advances under term loans and RIPSA are contingent on achieving commercial milestones.

• Management expects continued growth and acceleration in Ohtuvayre use, with 2025 anticipated as a significant year.

• No formal revenue guidance for Q4 or 2025 was provided, but transparency and future updates were promised.